HTGAA 2025 Week 12 || Frugal Science, Microfluidics, & the Microbiome |
Thnx #StanfordProfManuPrakash @PrakashLab for 4/29/25 https://2025.htgaa.
https://x.com/WorldUnivAndSch/
https://x.com/Q_YogaMacFlower/
https://x.com/scottmacleod/
https://x.com/HarbinBook/
https://x.com/sgkmacleod/
https://x.com/WUaSPress/
#ExtremeLongevityDial #VirtualDrosophila >2X ~max age, #AgingReversalTimeSlide #RealisticVirtualDrosophilaFly back' to 30 days w #FruitFly #AvatarAgentElectronicHealthRecords w #GPegman in #GStreetView w #GTimeSlider in #WUHighPerformance #RealisticVirtualEarth #ForAgingReversal~ https://t.co/SWCyWUN3aT
— WorldUnivandSch (@WorldUnivAndSch) April 29, 2025
https://x.com/WUaSPress/
https://x.com/scottmacleod/
https://x.com/Q_YogaMacFlower/
https://x.com/WorldUnivAndSch/
https://www.linkedin.com/
https://www.linkedin.com/
@GoogleDeepMind
We built an AI model to simulate how a fruit fly walks, flies and behaves – in partnership with
@HHMIJanelia
.

Our computerized insect replicates realistic motion, and can even use its eyes to control its actions.
Here’s how we developed it – and what it means for science.

We built an AI model to simulate how a fruit fly walks, flies and behaves – in partnership with @HHMIJanelia. 🪰
— Google DeepMind (@GoogleDeepMind) April 23, 2025
Our computerized insect replicates realistic motion, and can even use its eyes to control its actions.
Here’s how we developed it – and what it means for science. 🧵 pic.twitter.com/wydgiJa19X
https://x.com/GoogleDeepMind/
- Methuselah (mth): This G protein-coupled receptor, when partially mutated, extends lifespan.
- Indy: This amino acid transporter, when mutated, also extends lifespan.
- InR and Chico: These genes are involved in the Insulin/IGF signaling pathway, and mutations in them can lead to longer lifespans.
- Superoxide dismutase: This antioxidant enzyme plays a role in extending lifespan.
- Sirt6: Overexpression of this protein, which is involved in DNA repair and metabolism, extends lifespan.
- Foxo: This transcription factor, similar to mammalian FOXO3, is a key player in regulating the insulin signaling pathway and is linked to longevity.
- dilp1 and dilp2: These genes, encoding insulin/IGF-like peptides, interact to influence lifespan and metabolism.
- This involves monitoring the survival of flies over time under specific conditions (temperature, food, etc.).
- Comparing gene expression profiles between young and old flies or between flies with different longevity traits can identify genes that change with age or are associated with longevity.
- Mutating specific genes and observing the resulting changes in lifespan can help pinpoint genes involved in aging and longevity.
- Measuring other relevant traits like stress resistance, immune response, or metabolism, in addition to lifespan, can provide a more comprehensive picture of aging and longev
https://wiki.
Plesa, Alexandru M., Michael Shadpour, Ed Boyden & George M. Church. 2023. [https://t.co/fNn62A28Jx Transcriptomic reprogramming for neuronal age reversal], Heidelberg, Germany: https://t.co/g56InwDUFq. Just #WikiAdded this to https://t.co/hJoNCLZNoK & an #AgingReversalMachine? https://t.co/E6lCQGiXx9
— WorldUnivandSch (@WorldUnivAndSch) June 2, 2024
https://x.com/WorldUnivAndSch/
https://x.com/scottmacleod/
https://twitter.com/
Retweeting -
Alex Plesa
@amplesa
Can we reverse aging?
7 yrs ago, Ocampo et al. showed that partial reprogramming can ameliorate aging hallmarks. But, OSKM induction has safety limitations & no new factors have emerged since. Here, https://biorxiv.org/


https://x.com/amplesa/status/
Dear HTGAA 2025,I hope you all enjoyed a fantastic week in the lab at Waters working with their Mass Spec tools! I look forward to the homework review and seeing how your experiments went. And to the entire Waters team—THANK YOU so much again for all of your hard work, creativity, and dedication to our students, we appreciate you so much!This week we are thrilled and honored to have joining us Professor Manu Prakash from Stanford, pioneer and champion of frugal science, and also former graduate of the Media Lab. I will also give a lecture on microfluidics and the microbiome.Our agenda Tuesday is as follows:E14-3412:05-3:05p ET: Homework Review & Final Project Discussion3:05-3:15p ET: BREAK3:15-4:15p ET: Manu4:15-5:00p ET: DavidFor MIT and Harvard students, in addition to your Measurement & Imaging homework, please also come prepared to share your EXPERIMENTAL PLANS for Tuesday. What are the details of the first experiments you will be conducting? Where will you be performing them? If there is time after homework review, we will spend time on final project feedback and preparation for the last two weeks of lab work!See you on Tuesday!Best,David--------------
David Sun Kong, Ph.D.
Director
Community Biotechnology Initiative
MIT Media Lab
--
* * *
#ExtremeLongevityDial #VirtualDrosophila >2X ~max age, #AgingReversalTimeSlide #RealisticVirtualDrosophilaFly back' to 30 days w #FruitFly #AvatarAgentElectronicHealthRecords w #GPegman in #GStreetView w #GTimeSlider in #WUHighPerformance #RealisticVirtualEarth #ForAgingReversal~
#ExtremeLongevityDial #VirtualDrosophila >2X ~max age, #AgingReversalTimeSlide #RealisticVirtualDrosophilaFly back' to 30 days w #FruitFly #AvatarAgentElectronicHealthRecords w #GPegman in #GStreetView w #GTimeSlider in #WUHighPerformance #RealisticVirtualEarth #ForAgingReversal~ https://t.co/mNXc3f0qhG
— HarbinBook (@HarbinBook) April 29, 2025
https://x.com/HarbinBook/
https://x.com/WUaSPress/
https://x.com/sgkmacleod/
https://x.com/scottmacleod/
https://x.com/Q_YogaMacFlower/
https://x.com/WorldUnivAndSch/
https://www.linkedin.com/
https://www.linkedin.com/
@GoogleDeepMind
We built an AI model to simulate how a fruit fly walks, flies and behaves – in partnership with
@HHMIJanelia
.

Our computerized insect replicates realistic motion, and can even use its eyes to control its actions.
Here’s how we developed it – and what it means for science.

EEEF
https://x.com/GoogleDeepMind/
@GoogleDeepMind
We built an AI model to simulate how a fruit fly walks, flies and behaves – in partnership with
@HHMIJanelia
.

Our computerized insect replicates realistic motion, and can even use its eyes to control its actions.
Here’s how we developed it – and what it means for science.

EEEF
https://x.com/GoogleDeepMind/
Retweeting -
Our computerized insect replicates realistic motion, and can even use its eyes to control its actions.
Here’s how we developed it – and what it means for science.
https://x.com/GoogleDeepMind/
* * *
COO: Ann Lee-Karlon
Location: California, USA
Founded in 2021 and backed by Jeff Bezos, Altos Labs focuses on cellular rejuvenation. Using Yamanaka factors, the company aims to reprogram cells to a youthful state, reversing signs of aging. By 2025, Altos Labs has initiated human clinical trials targeting neurodegenerative and immune-related aging disorders, positioning itself as a leading longevity startup in the world.
2. Insilico Medicine
CEO: Alex Zhavoronkov
Location: Hong Kong
Insilico Medicine combines AI with biology to discover novel longevity treatments. Its platform, Pharma.AI, has yielded drug candidates for age-related diseases such as idiopathic pulmonary fibrosis. As of 2025, its first AI-discovered drug is in Phase 2 trials, attracting attention as a promising longevity stock.
3. Unity Biotechnology
CEO: Anirvan Ghosh
Location: California, USA
Specializing in senescence-targeted therapies, Unity Biotechnology develops drugs to remove senescent cells, which drive aging and disease. Its lead drug for "age reversal unity" therapies has shown significant progress, with Phase 2 results indicating improved outcomes in diabetic macular edema.
4. BlueRock Therapeutics
CEO: Seth Ettenberg
Location: Massachusetts, USA
A subsidiary of Bayer, BlueRock Therapeutics uses biotechnology aging to regenerate damaged tissues. It is an industry leader in creating induced pluripotent stem cells (iPSC) used in neurology, cardiology, and immunology. BlueRock has developed a one-of-a-kind cell+gene that reprograms mature cells back to iPSC’s and enhances their therapeutic capabilities. Advanced bioprocess techniques are then used to re-differentiate these iPSCs, which can replace damaged or diseased cells. By 2025, the company has advanced clinical trials for Parkinson’s disease and myocardial repair, strengthening its presence as an anti aging biotech leader.
5. Calico Life Sciences
CEO: Hal Barron
Location: California, USA
A flagship project of Alphabet, Calico Life Sciences (or Calico Biotechnology) focuses on understanding the molecular and cellular mechanisms of aging. It develops technologies intended to better understand the biology that governs one’s lifespan. The company's services are focused on the health and well-being of persons suffering from aging-related diseases, with the goal of reducing their effects and allowing people to live long and healthy lives. In 2025, Calico continues its partnership with AbbVie to develop treatments targeting neurodegenerative diseases, with a strong pipeline of longevity treatments.
6. Elevian
CEO: Mark Allen
Location: Massachusetts, USA
Elevian develops regenerative medicine aimed at preventing and treating age-related disorders by identifying blood factors that regulate aging and stimulating the body's natural repair and regeneration mechanisms. It focuses on GDF11-based therapies to regenerate tissue and improve vascular and cognitive health. Its lead drug has entered Phase 2 trials, making it a sought-after name in anti aging stocks for its potential to reshape the longevity biotech space.
7. LyGenesis
CEO: Michael Hufford
Location: Pennsylvania, USA
LyGenesis develops cell treatment technology for organ regeneration and transplantation. The technology focuses on liver regeneration for patients with end-stage liver disease, allowing surgeons to rebuild functional organs within a patient's own body using lymph nodes. In 2025, its liver regeneration program for end-stage liver disease has entered Phase 2 trials, marking a breakthrough in the longevity market.
8. Juvenescence
CEO: Gregory Bailey
Location: Isle of Man, UK
Juvenescence develops therapies specializing in aging disorders and increasing human longevity. The company's therapies promote healthy lifestyles, allowing patients to slow or reverse aging. It invests in longevity startups focusing on mitochondria-targeted therapies, AI drug discovery, and ketone ester drinks. Its "Metabolic Switch" product is a pioneer in innovative lifestyles, promoting metabolic health for extended lifespans.
9. Oisin Biotechnologies
CEO: Matthew Scholz
Location: Washington, USA
Oisin Biotechnologies develops senolytic therapies intended to reduce the consequences of aging. The company's technique employs an unique proteo-lipid vehicle drug delivery platform to induce apoptosis in a senescent cell without hurting nearby healthy cells, allowing clinicians to tackle age-related disorders. By 2025, Oisin’s proprietary drug delivery platform has entered Phase 1 trials for cardiovascular aging, positioning it as a standout longevity company.
10. Human Longevity
CEO: Cynthia Collins
Location: California, USA
Human Longevity uses its platform that combines genetic and phenotypic data to better understand human health. The platform can address age-related decline in endogenous stem cell function and focuses on shifting medicine for diseases like cancer, diabetes, dementia, and obesity from reactive to proactive technologies. In 2025, its AI-driven predictive analytics platform, known as the Human Longevity Lab, has been instrumental in shifting medicine from reactive to proactive care, boosting human longevity stock value.
11. Repair Biotechnologies
CSO: Mourad Topors
Location: New York, USA
Repair Biotechnologies develops gene and protein therapies to reverse age-related thymic atrophy and the loss of immunological function that follows, allowing people to live longer by addressing the causes of age-related diseases and aging itself. It is developing therapies to reverse age-related thymic atrophy and improve cardiovascular health. By 2025, its preclinical data has shown success in reversing atherosclerosis, positioning it as a key player in the regeneration-focused longevity biotech space.
12. Life Biosciences
CEO: Jerry McLaughlin
Location: Massachusetts, USA
Life Biosciences tackles the eight hallmarks of aging by developing longevity treatments focused on cellular rejuvenation and metabolic optimization. It develops drugs specializing in promoting longevity and developing remedies for age-related disorders. The company's drugs are intended to counteract the eight pathways of age-related decline. Its 2025 research initiatives include mitochondrial repair therapies and advanced senescence-inhibiting drugs, making it a standout in longevity stocks.
13. Acorn Biolabs
CEO: Drew Taylor
Location: Canada
Acorn Biolabs provides cell preservation services for non-invasive cell freezing that can be used for future medical applications. Consumers will have access to regenerative medicine, genetics, and powerful stem cell therapy in the future thanks to the company's services. It offers cutting-edge, non-invasive cell preservation services that allow consumers to store healthy cells for future regenerative therapies. In 2025, Acorn has expanded its global presence and launched advanced cryopreservation technologies aimed at supporting innovative lifestyles and personalized longevity solutions.
14. Turn.bio
CEO: Anja Krammer
Location: California, USA
Turn.bio focuses on longevity tech through epigenetic reprogramming, rejuvenating cells at the molecular level. By 2025, its therapies targeting skin rejuvenation and hair regrowth have entered clinical trials, creating a strong foothold in the anti aging technology market.
15. Cambrian Biopharma
CEO: James Peyer
Location: New York, USA
Cambrian Biopharma is a distributed biotech company working on a portfolio of longevity treatments. By 2025, it has advanced multiple drugs into Phase 2 trials, including therapies targeting chronic inflammation and fibrosis, making it a promising choice for investors seeking anti aging stocks.
16. NaNotics
CEO: Louis Hawthorne
Location: California, USA
NaNotics has developed a nano platform to treat solid tumor malignancies and autoimmune illnesses. The platform uses nano-extractors that remove specific circulating molecular signals or signal inhibitors that drive or enable disease progression. This allows doctors to provide patients with a safe treatment option. It develops nano-extractors that selectively remove harmful molecules from the body, addressing age-related diseases at their root. In 2025, its collaborations with major pharmaceutical companies have paved the way for scalable production, marking a significant leap in biotechnology aging.
17. CohBar
CEO: Joe Sarret
Location: California, USA
CohBar Inc is developing mitochondria-based therapeutics (MBTs) to treat several age-related and metabolic dysfunction diseases like nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases, cancer and acute respiratory distress syndrome (ARDS).
18. Leucadia Therapeutics
CEO: Doug Ethell
Location: California, USA
Leucadia Therapeutics has developed a medical technology platform aimed at providing unique and enhanced Alzheimer's disease treatments. It is focused on developing Alzheimer's disease therapies by addressing cerebrospinal fluid flow. By 2025, the company is leading the charge in innovative Alzheimer's solutions in the longevity biotech sector.
19. BioSplice Therapeutics
CEO: Cevdet Samikoglu
Location: California, USA
BioSplice Therapeutics is a tissue-level therapeutic medication company that aims to heal degenerative patients by identifying new targets and biological processes in the Wnt pathway, allowing them to create small molecule medications intended to treat a variety of degenerative diseases and cancers. Its osteoarthritis treatment, Lorecivivint, has achieved significant Phase 3 success in 2025, elevating its profile in the anti aging technology market.
20. Celularity
CEO: Robert Hariri
Location: New Jersey, USA
Cellularity develops off-the-shelf placental-derived allogeneic cell therapies, such as genetically modified and unmodified NK cells, engineered T cells for cancer, immunologic, infectious, and degenerative diseases. It develops cell-based therapies derived from the placenta to address degenerative and cancer-related diseases. In 2025, its expansion into neurodegenerative conditions has further cemented its reputation as a key longevity company innovating in regenerative medicine.
--
*
https://en.wikipedia.org/wiki/Northern_spotted_owl
https://commons.wikimedia.org/wiki/Category:Strix_occidentalis
...
No comments:
Post a Comment